Live
- Funds allocated for development works: Collector Venkatesh Dhotre
- Govt Whip lays foundation for several development works
- Botcha distributes cheques to diarrhoea victims’ kin
- Horoscope Today: November 27, 2024. Get Your Horoscope for All Zodiac Signs
- Are strict laws needed to ensure MLAs attend Assembly sessions?
- Special prayers held at Devatparambu ahead of Kodava National Day
- Theft in Tirumala temple’s hundi caught on camera
- Sharmila takes out rally to mark Constitution Day
- Bypoll results not a mandate for the State govt: Bommai
- Deputy CM seeks increase in estimates in NREGS works
GNH Imports Life-Saving Medicine to India
India’s most accredited pharmaceutical wholesaler, GNH India has successfully imported a life-saving medicine called Olaratumab (trade name Lartruvo) that is now available through official import channels.
• Leading Pharmaceutical wholesaler GNH imports life-saving ‘orphan drug’ status
• An Orphan drug is named so as it is not easily available globally
• This drug is used to fight solid tumors and soft tissue sarcomas
India: India’s most accredited pharmaceutical wholesaler, GNH India has successfully imported a life-saving medicine called Olaratumab (trade name Lartruvo) that is now available through official import channels.
It is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. The cost of each injection isapproximately Rs. 1,72,500.
Dr Piyush Gupta, Associate Director, GNH India commented, “GNH India has always believed that everyone should have access to proper healthcare and medicines, and we strive to deliver the same to the people irrespective of the global boundaries. In this effort we have aimed to import a rare orphan status drug called, ‘Olaratumab’ that is used to treat soft tissue sarcoma. It gives us tremendous pleasure to be the first Indian specialized wholesaler to provide this life-saving medicine in India and we look forward to many more opportunities”
This drug is classified ‘Orphan drug’as it is not available easily world-wide.In February 2015, the European Medicines Agency assigned Olaratumab ‘orphan drug’ status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorization, based on a Phase II study, valid throughout the European Union on 9 November 2016.
